- Home
- LFUS vs ACLX Comparison
LFUS vs ACLX Comparison
Compare LFUS & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFUS
- ACLX
- Stock Information
- Founded
- LFUS 1927
- ACLX 2015
- Country
- LFUS United States
- ACLX United States
- Employees
- LFUS N/A
- ACLX N/A
- Industry
- LFUS Electrical Products
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- LFUS Energy
- ACLX Health Care
- Exchange
- LFUS Nasdaq
- ACLX Nasdaq
- Market Cap
- LFUS 4.4B
- ACLX 3.5B
- IPO Year
- LFUS N/A
- ACLX 2022
- Fundamental
- Price
- LFUS $228.23
- ACLX $68.15
- Analyst Decision
- LFUS Buy
- ACLX Strong Buy
- Analyst Count
- LFUS 5
- ACLX 14
- Target Price
- LFUS $252.25
- ACLX $111.42
- AVG Volume (30 Days)
- LFUS 147.5K
- ACLX 507.8K
- Earning Date
- LFUS 07-29-2025
- ACLX 08-07-2025
- Dividend Yield
- LFUS 1.22%
- ACLX N/A
- EPS Growth
- LFUS N/A
- ACLX N/A
- EPS
- LFUS 3.81
- ACLX N/A
- Revenue
- LFUS $2,209,690,000.00
- ACLX $76,809,000.00
- Revenue This Year
- LFUS $6.40
- ACLX N/A
- Revenue Next Year
- LFUS $7.76
- ACLX $112.68
- P/E Ratio
- LFUS $60.24
- ACLX N/A
- Revenue Growth
- LFUS N/A
- ACLX N/A
- 52 Week Low
- LFUS $142.10
- ACLX $47.86
- 52 Week High
- LFUS $275.58
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- LFUS 52.71
- ACLX 57.56
- Support Level
- LFUS $230.32
- ACLX $67.46
- Resistance Level
- LFUS $241.63
- ACLX $70.81
- Average True Range (ATR)
- LFUS 5.93
- ACLX 2.19
- MACD
- LFUS -0.83
- ACLX 0.30
- Stochastic Oscillator
- LFUS 37.59
- ACLX 67.20
About LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) into the transportation, industrial, telecommunications, and consumer electronics end markets. The firm is also increasing its power semiconductor business, where it predominantly serves industrial end markets and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.